- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02330003
Phase 1 Study to Assess the Safety of Inactivated Split Influenza Vaccine and Control Vaccine in Korean Volunteer
A Randomized, Active-Comparator, Open-Label, Phase 1 Clinical Trial to Assess the Safety of the 'IL-YANG Inactivated Split Influenza Vaccine' and Fluarix Prefilled Syringe in Healthy Korean Male Volunteer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a randomized, open-label, active-controlled clinical study. After providing voluntary written informed consent, subjects underwent protocol-specific assessments and tests within the 4 weeks prior to administration of the study vaccine, and those who met all of the inclusion/exclusion criteria were randomized sequentially to the test group or the comparator group according to the pre-generated randomization code. To investigate the safety of the study drug with a two-dose regimen in children, the test group received another dose 28 days after the first dose.
The investigator evaluated the safety and immunogenicity for each subject throughout the study. Safety assessments were performed 28 days after the first dose (Visit 4, End-of-Study Visit) for the comparator group receiving a single-dose regimen of Fluarix Prefilled Syringe, and for the test group receiving a two-dose regimen of the test drug, 28 days after the first dose (Visit 4) and 28 days after the second dose (Visit 6, End-of-Study Visit). Subjects were instructed to record any adverse event occurring after vaccination in the Patient Diary Card. For the immunogenicity assessment, an antibody titer test was performed prior to dosing at Visit 2 (baseline) and 28 days (Visit 4) after the first vaccination for both the test group and comparator group.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male subjects between 20 and 55 years of age at screening
- Body weight of ≥ 55kg and within ±20% of ideal body weight (ideal body weight = (height cm - 100)*0.9) at screening
- Subjects with no congenital or chronic disease who were considered suitable for the study after screening assessments (investigator's opinion, medical history, physical examination, laboratory test, chest X-ray, and ECG) conducted within 28 days prior to vaccination
- Subjects who were given, and fully understood, the information about the study, made a voluntary decision, and provided written informed consent, to participate in the study and comply with all applicable study requirements
Exclusion Criteria:
- Subjects who have known or suspected infection with HAV, HBV, HCV, HIV or VDRL
- Subjects who have concurrent or a past history of immune deficiency disease
- Subject who had participated in blood donation within 1 week prior to vaccination, or are planning to participate in blood donation from Day 1 until Month 7 post-vaccination
- Subject with a history of Guillain-Barre syndrome
- Subject with hemophilia or thrombocytopenia, or being treated with an anticoagulant, who are at increased risk of serious bleeding during intramuscular injection
- Subjects who have concurrent or a past history of, malignant tumor of internal organ or blood vessels or skin metastasis
- Subjects with known allergy to a drug, food or latex, who had a history of anaphylaxis
- Subjects who had an acute fever with body temperature > 38.0 Cº within 72 hours prior to administration of the study vaccine or symptoms of suspected acute disease within 14 days prior to administration of the study vaccine
- Subjects who received another experimental drug or vaccine within 28 days before administration of the study vaccine or are planning to receive another experimental drug or vaccine during the study.
- Subjects who had previously received immunoglobulin or blood-derived products within the last 3 months prior to administration of the study vaccine, or are expecting to be treated with immunoglobulin or blood-derived products during the study
- Subjects who had received, or are scheduled to receive, systemic immunosuppressive therapy, radiation therapy or high-dose corticosteroid therapy within the last 6 months prior to administration of the study
- Subjects with a history of, or suspected, drug abuse based on subject interview and physical examination.
- Subjects with excessive consumption of caffeine and alcohol and excessive smoking
- Subject with a known allergy to eggs, chicken, or any components of the study vaccine
- Subjects who in the investigator's opinion, may not be suitable for vaccination or who may interfere with the objective assessment of the study outcomes.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IL-YANG PFS
IL-YANG FLU Vaccine Prefilled Syringe INJ.
|
Second vaccination (only for the test group) of IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL
|
Active Comparator: TIV PFS
Fluarix Prefilled Syringe
|
Fluarix Prefilled Syringe 0.5mL
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of subjects achieving seroconversion and seroprotection for HI antibody after administration of the study vaccine
Time Frame: up to Day28(+7)
|
Seroconversion: a pre-vaccination (Day 0) hemagglutination-inhibition (HI) antibody titer < 1:10 and a post-vaccination (Day 28) HI antibody titer ≥ 1: 40 (Case 1), or a pre-vaccination (Day 0) HI antibody titer ≥ 1:10 and a minimum four-fold rise in post-vaccination (Day 28) HI antibody titer (Case 2). Seroprotection: post-vaccination (Day 28) HI antibody titer ≥ 1:40 |
up to Day28(+7)
|
Solicited local & general Adverse Event, Unsolicited Adverse Event
Time Frame: up to Day28(+7)
|
Solicited local reaction: pain, tenderness, redness, swelling, Solicited general reactions: fever, nausea/vomiting, diarrhea, headache, fatigue, myalgia
|
up to Day28(+7)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vital signs
Time Frame: up to Day28(+7)
|
up to Day28(+7)
|
|
Physical examination
Time Frame: up to Day28(+7)
|
up to Day28(+7)
|
|
ECG result
Time Frame: up to Day28(+7)
|
up to Day28(+7)
|
|
Clinical laboratory results
Time Frame: up to Day28(+7)
|
up to Day28(+7)
|
|
GMT of HI antibody titer before vaccination and after vaccination
Time Frame: up to Day28(+7)
|
Geometric Mean Titer (GMT), as measured by pre-vaccination (Day 0) HI antibody titer and post-vaccination (vaccination + 28 days) HI antibody titer.
|
up to Day28(+7)
|
GMR of HI antibody titer before vaccination and after vaccination
Time Frame: up to Day28(+7)
|
Geometric Mean Ratio (GMR), as measured by pre-vaccination (Day 0) HI antibody titer and post-vaccination (vaccination + 28 days) HI antibody titer
|
up to Day28(+7)
|
Percentage of subjects with a pre-vaccination (Day 0) HI antibody titer < 1:40, and a minimum four-fold rise in post-vaccination (Day 28) HI antibody titer
Time Frame: up to Day28(+7)
|
up to Day28(+7)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Min Soo Park, M.D,PhD, Severance Hospital, Yonsei University Health System
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IY_IFEZ_102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on IL-YANG FLU Vaccine Prefilled Syringe INJ.
-
Il-Yang Pharm. Co., Ltd.Completed
-
Il-Yang Pharm. Co., Ltd.Completed
-
Il-Yang Pharm. Co., Ltd.Not yet recruiting
-
Il-Yang Pharm. Co., Ltd.Completed
-
Il-Yang Pharm. Co., Ltd.CompletedInfluenza, HumanKorea, Republic of
-
Il-Yang Pharm. Co., Ltd.CompletedHealthyKorea, Republic of
-
Il-Yang Pharm. Co., Ltd.Completed
-
Boryung Pharmaceutical Co., LtdCompletedPertussis | Tetanus | Diphtheria | PoliomyelitisThailand, Korea, Republic of
-
Green Cross CorporationCompletedInfluenzaKorea, Republic of
-
Green Cross CorporationCompleted